Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)
China
· Delayed Price · Currency is CNY | Market Cap | 30.70B |
| Revenue (ttm) | 2.50B |
| Net Income (ttm) | -874.39M |
| Shares Out | n/a |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,303,097 |
| Average Volume | 14,222,683 |
| Open | 33.20 |
| Previous Close | 34.00 |
| Day's Range | 31.68 - 33.47 |
| 52-Week Range | 25.60 - 51.40 |
| Beta | 0.79 |
| RSI | 31.99 |
| Earnings Date | Mar 14, 2026 |
About SHA:688180
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China. [Read more]
Financial Performance
In 2024, SHA:688180's revenue was 1.95 billion, an increase of 29.67% compared to the previous year's 1.50 billion. Losses were -1.28 billion, -43.90% less than in 2023.
Financial StatementsNews
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study
TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatme...
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...